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EDITORIAL
Divining progression in Parkinson disease with
a blood test
NfL





In their article in this issue of Neurology®, Lin and colleagues1 provide compelling evidence for
the utility of a neurofilament light chain (NfL) blood test in predicting progression in Parkinson
disease (PD) and in distinguishing PD from multisystem atrophy (MSA). If confirmed by
independent studies, this would be a major advance for clinical and basic research. Such a test
also may have complex consequences for clinical care.
Available tools for prognosis in PD are limited. Clinical factors, including advanced disease at
diagnosis, male sex, and advanced age, are associated with more rapid progression.2 The utility
of classifying PD phenotypes into tremor-predominant relatively benign, compared to postural-
instability gait disorder relatively more rapidly progressive, has been questioned.3 Genetic
variation and CSF biomarkers (mainly α-synuclein) have shown utility as biomarkers of PD
progression.2,4 Imaging and multimodal risk modeling may also be useful.2,4 However, none of
these biomarkers are universally accepted, and some are limited to specific patient populations.
Nf L is a an abundant neuronal cytoskeletal protein. There has been much interest in NfL as
a biomarker for neurologic injury, particularly in Alzheimer disease, inherited peripheral neu-
ropathy, multiple sclerosis, amyotrophic lateral sclerosis, and acute brain injury.5 Most of this
research has been based onNfL as measured from the CSF.More recently, a good correlation of
NfL levels in CSF and serum has been reported.5
The Chin et al. study prospectively enrolled 178 participants, including 116 with PD, 22 with
MSA, and 40 healthy controls. The study cohort may be small for stroke, but for PD/MSA, this
is a substantially sized cohort, and follow-up averaged 3 years. The correlation of motor and
cognitive status andNfL was found both cross-sectionally and longitudinally. In addition, serum
NfL levels distinguished MSA from PD. The authors were able to establish a cutoff level that
separated participants with PD with stable disease at 3 years from those who progressed. There
was marked divergence in Kaplan-Meier–plotted clinical trajectories for both motor and
cognitive symptoms. At the end of the 3-year study, motor progression occurred among all
participants with PD with baseline NfL levels ≥21.84 pg/mL, while only about half of patients
with lower NfL levels showed progression. Cognitive progression occurred by the end of the
study period in all participants with NfL ≥18.34 pg/mL and among approximately one-third of
those with lower NfL levels. Hence, NfL levels more robustly foretell bad than good news.
A caveat here is that the definitions of motor and mental decline on the United Parkinson’s
Disease Rating Scale part III (decline of >2 points) and Mini-Mental State Examination (<26
points) were not necessarily of a magnitude that would reach clinical relevance; in fact, studies
designed to address the changes that make clinically important differences using these measures
suggest that these changes may not be clinically important.6,7 However, over the 3-year period
of the study, the difference between progressors and nonprogressors was increased. Further
longitudinal follow-up and confirmation are needed to determine whether these divergent
trajectories persist.
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While NfL levels distinguished PD from healthy controls and
patients with MSA from those with PD, it needs to be em-
phasized that all participants met clinical diagnostic criteria for
PD orMSA by the time of entry into the study. Hence, while it
raises hopes for the future, the present study was not designed
to address the usefulness of NfL for early diagnosis of either
PD or MSA.
Emerging technologies to predict future risk are not them-
selves without risk.8 Experience from other tests to predict
neurologic diseases, while not fully analogous, suggest that,
with careful consideration, not all persons want to know what
the future holds and that predictive testing can have adverse
effects even for those whose results yield “good news.”
The model for Huntington disease involving extensive pretest
and posttest counseling has been proposed for other types of
predictive testing.8 Advances in technology will make more
predictive tests available. At the same time, an increasingly
skeptical public is leaning away from “whatever you say, doc”
and toward other information sources, including the internet.
Whole-body CTs and MRIs are available for “screening” on
the private market. Similarly, genetic profiles are proposed by
private companies as being able to identify a large range of
risks, including hereditary cancers and degenerative diseases.
Risk profiles, albeit of uncertain accuracy, are available directly
to consumer and are widely used.9 These are tricky waters to
navigate. Further research is needed not only to define the
value of NfL as a surrogate biomarker for PD progression but
also to understand the clinical import and social ramifications
of the availability of predictive testing in neurology. If con-
firmed, the present data would suggest that the practicing
neurologist would have a test to robustly predict progression
but likely not to reassure nonprogressors.
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